Summary: HEMAY PHARMA-B (00054) reported Operating profit of -129.03M（-5.89%）; Net profit attributable to owners of -129.81M（-5.20%）.
ReportedYoY
Prior YearYoY
Operating profitDown YoY
-129.03M5.89%
-121.85M--
Net profit attributable to ownersDown YoY
-129.81M5.20%
-123.39M--
Operating profit
ReportedUnit: CNY
Net profit attributable to owners
ReportedUnit: CNY
ROEYoY
Unit: CNY
FY 2024
FY 2025
Profitability
(YoY)
Growth
(YoY)
Asset Quality
(YoY)
Cash Generation
(YoY)
Other income and gainsYoY
Unit: CNY
FY 2024
FY 2025
Revenue
(YoY)
Expenses
(YoY)
Interest
(YoY)
Income Tax
(YoY)
Profit
(YoY)
Cash and cash equivalentsYoY
Unit: CNY
FY 2024
FY 2025
Assets
(YoY)
Liabilities
(YoY)
Equity
(YoY)
Net cash from operating activitiesYoY
Unit: CNY
FY 2024
FY 2025
Operating Cash Flow
(YoY)
Investing Cash Flow
(YoY)
Financing Cash Flow
(YoY)
Net Change in Cash
(YoY)
Financial data: HKEXnews annual and interim reports; pre-listing years from the prospectus. YoY for ratios is the change in percentage points; ROE and ROA use annual reports only.
About this page
This page shows HEMAY PHARMA-B (00054) historical financial statements and corporate actions. Financial data comes from public financial disclosures in HKEX display documents, grouped by reporting period; corporate actions come from HKEXnews announcements.
